Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen Peptide Vaccine in Pancreatic Cancer
NCT03956056Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2020
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in pancreatic adenocarcinoma (PDAC), sponsored by Washington University School of Medicine. Primary endpoint: Serious Adverse Events. Started Feb 2020; status: terminated.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03956056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03956056.